Expression of CD11b, CD25, CD95 and HLA-DR in the leucocytes during the course of antibacterial therapy in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 480s Year: 2002
Severe pneumonia mortality in pediatric patients is associated with downregulation of Toll-like receptors 2 and 4 on monocytes Source: International Congress 2016 – Neonatal and paediatric multiorgan manifestations of acute and chronic pulmonary disease and use of treatments Year: 2016
Acute phase proteins (APP) and serum iron in patients (pts) with simple community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 805s Year: 2006
Interleukin-2 (IL-2) and interferon-γ(IF-γ) in idenitying severe community-acquired pneumonia (SCAP) clinical outcomes and complications Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011
Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002
Discharge delay in patients with community-acquired pneumonia (CAP) treated with a pneumonia critical pathway Source: Eur Respir J 2002; 20: Suppl. 38, 560s Year: 2002
Soluble forms of CD95 (fas/apo-1), cd38 and CD25 antigens in patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pleural and parenchymal diseases Year: 2009
Impact of neutrophil function on outcomes of community-acquired pneumonia (CAP) in patients with cancer Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007
Level of hypoferremia at patients with community-acquired pneumonia (CAP) and lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 438s Year: 2007
The death receptor CD95 (Fas, Apo-1) expression and Annexin-V binding of phosphatidylserine in lymphocytes in bronchial asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 757s Year: 2006
Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 418s Year: 2002
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections Source: Eur Respir J 2004; 24: 247-250 Year: 2004
Diagnostic value of serum soluble interleukin-2 receptor (SIL- 2R) and acute phase proteins levels (APP) in community acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003
IgG Fcγ receptor expression on BAL neutrophils, pneumonia, and HIV-infection Source: Eur Respir J 2003; 22: Suppl. 45, 333s Year: 2003
C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005
Role of virus in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Fungal, viral and other infections Year: 2012
Serum levels of IL-6 in severe community-acquired pneumonia Source: Annual Congress 2010 - Pulmonary infections and sepsis Year: 2010
Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections Source: Eur Respir J 2006 Oct 01;28(4):695-702 Year: 2006
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
Triggering receptor expressed on myeloid cells (TREM)-1 and its soluble form (sTREM-1) as a diagnostic marker of bacterial lung infection Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008